JACC This Week podcast

Monotherapy in HBR Patients: What STOPDAPT-3 Tells Us | JACC Baran

0:00
31:30
Rewind 15 seconds
Fast Forward 15 seconds

Hosts Mitsuaki Sawano, MD, Kentaro Ejiri, MD, and Nobuhiro Ikemura, MD, welcome Yuki Obayashi, MD, of Leiden University Medical Center, to discuss findings from the STOPDAPT-3 trial. Dr. Obayashi highlights that, among ACS patients—including those with HBR or STEMI—aspirin and clopidogrel monotherapy after 1 month of DAPT resulted in similar rates of ischemic and bleeding events. These results support flexible, patient-centered antiplatelet strategies beyond the acute phase.

More episodes from "JACC This Week"